- $15.57bn
- $14.73bn
- $2.32bn
Brief: Exelixis says Detailed Results From Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib In Advanced Neuroendocrine Tumors Presented At ESMO 2023
Brief: Exelixis And Insilico Medicine Enter Into Agreement For ISM3091
Brief: Exelixis Announces Positive Results From Phase 3 Cabinet Pivotal Trial
U.S. RESEARCH ROUNDUP-Appfolio, Iron Mountain, Neogenomics
U.S. STOCKS ON THE MOVE-Natgas firms, Moderna, VinFast
U.S. STOCKS ON THE MOVE-Energy firms, copper miners, natgas firms
Exelixis gains after cancer drug meets late-stage trial goal
Brief: Exelixis And Ipsen Announce Positive Results From Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib In Combination With Atezolizumab
Exelixis Inc reports results for the quarter ended in June - Earnings Summary
Brief: Exelixis Q2 Revenue USD 469.8 Million Vs. IBES Estimate USD 445.4 Million
Exelixis Inc expected to post earnings of 16 cents a share - Earnings Preview
Exelixis Inc reports results for the quarter ended in March - Earnings Summary
Brief: Exelixis Q1 revenue USD 408.8 million
Brief: Exelixis Announces First Quarter 2023 Financial Results And Provides Corporate Update
Brief: Farallon Capital Says Urge Exelixis Shareholders To Vote "For" Each Of Farallon Nominees
Exelixis, facing challenge from Farallon, says Willsey to exit board
Brief: Exelixis Announces Departure Of Lance Willsey, M.D. From Board Of Directors
Exelixis Inc expected to post earnings of 15 cents a share - Earnings Preview
Brief: Farallon Capital Urges Exelixis Shareholders To Elect Its Three Director Candidates